Huang Kuan-Yeh, Ng Kwai-Fong, I Kuan-Yu, Chang Yu-Chi, Chen Hsin-Yi, Chiu Ya-Fang, Hung Chuan-Mao, Yu Wan-Chen, Chen Tse-Ching, Stacey Martin, Lin Hsi-Hsien
Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Taoyuan City, 33302, Taiwan.
Department of Anatomic Pathology, Chang Gung Memorial Hospital-Linkou, Taoyuan, Taiwan.
Cell Commun Signal. 2025 May 29;23(1):251. doi: 10.1186/s12964-025-02267-z.
GPR56/ADGRG1 is an adhesion G protein-coupled receptor involved in cell-matrix interactions and metastasis of human melanoma cells. Previously, we demonstrated that GPR56 activation in melanoma cells triggers Gα-RhoA signaling, leading to increased IL-6 production and enhanced cell migration. Yet little is known of the downstream signaling effectors and their specific roles in regulating melanoma cellular phenotypes.
In this study, we show that GPR56 activation induces Rho-ROCK-MLC and JAK-STAT3 signaling, which temporally and differentially drive amoeboid-like morphology and IL-6 upregulation. Interestingly, GPR56-induced JAK-STAT3 activation is partially regulated by Rho-ROCK-MLC signaling but not vice versa. Moreover, receptor auto-proteolysis modulates the magnitude of GPR56-mediated signaling, and its unique intracellular regions contribute to the selective regulation of unique signaling pathways and associated cellular phenotypes.
Our findings reveal complex GPR56-mediated biased signaling through the Rho-ROCK-MLC and JAK-STAT3 pathways, highlighting these networks as potential therapeutic targets for modulating distinct tumorigenic phenotypes in human melanoma cells.
GPR56/ADGRG1是一种粘附性G蛋白偶联受体,参与人类黑色素瘤细胞的细胞-基质相互作用和转移。此前,我们证明黑色素瘤细胞中的GPR56激活会触发Gα-RhoA信号传导,导致白细胞介素-6(IL-6)产生增加和细胞迁移增强。然而,对于下游信号效应器及其在调节黑色素瘤细胞表型中的具体作用知之甚少。
在本研究中,我们表明GPR56激活会诱导Rho-ROCK-MLC和JAK-STAT3信号传导,它们在时间上和差异上驱动类阿米巴样形态和IL-6上调。有趣的是,GPR56诱导的JAK-STAT3激活部分受Rho-ROCK-MLC信号传导调节,反之则不然。此外,受体自身蛋白水解调节GPR56介导的信号传导强度,其独特的细胞内区域有助于对独特信号通路和相关细胞表型的选择性调节。
我们的研究结果揭示了通过Rho-ROCK-MLC和JAK-STAT3途径的复杂GPR56介导的偏向性信号传导,突出了这些网络作为调节人类黑色素瘤细胞中不同致瘤表型的潜在治疗靶点。